kabutan

KISSEI PHARMA, Last Fiscal Year's Ordinary Profit Unexpectedly Increases, 6% Increase in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 10 yen, This Fiscal Year to Increase Dividend by 20 yen

Wed May 7, 2025 4:30 pm JST Earnings

4547 KISSEI PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KISSEI PHARMACEUTICAL CO.,LTD. <4547> [TSE Prime] announced its financial results after the market closed on May 7th (16:30). The consolidated ordinary profit for the fiscal year ending March 2025 increased 13.5% from the previous period to 6.97 billion yen exceeding the previous forecast of 6 billion yen and resulted in an increase in profit, a complete reversal from the forecast for a decline in profit. For the fiscal year ending March 2026, the consolidated ordinary profit is expected to grow by 6.1% to 7.4 billion yen. This will be the fourth consecutive term of revenue and profit growth.

At the same time, the company increased the annual dividend for the previous term from 90 yen to 100 yen (compared to 82 yen in the prior term), and has decided to increase the dividend this fiscal year to 120 yen, an increase of 20 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit surged 40 times that of the same period last year, reaching 1.67 billion yen. The operating profit/loss margin drastically improved from -0.8% in the same period last year to 6.8%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 67,493 -1,129 598 10,528 228.3 80 May 8, 2023 J-GAAP
Mar, 2024 75,579 4,017 6,142 11,160 246.6 82 May 7, 2024 J-GAAP
Mar, 2025 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
YoY +16.9% +43.7% +13.5% +7.2% +11.2%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 86,500 5,000 6,000 11,700 273.3 90 Nov 5, 2024 J-GAAP
Mar, 2025 Results 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
Revision Rate +2.1% +15.5% +16.2% +2.2% +0.3%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 42,466 1,781 2,237 5,249 118.8 45 Nov 5, 2024 J-GAAP
Apr - Sep, 2025 Guidance 44,300 2,300 3,100 6,200 149.6 60 May 7, 2025 J-GAAP
YoY +4.3% +29.1% +38.6% +18.1% +26.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,579 4,017 6,142 11,160 246.6 82 May 7, 2024 J-GAAP
Mar, 2025 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
Mar, 2026 Guidance 91,500 6,000 7,400 12,300 296.7 120 May 7, 2025 J-GAAP
YoY +3.6% +3.9% +6.1% +2.8% +8.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 17,720 -147 42 2,823 62.4 -0.8 May 7, 2024 J-GAAP
Apr - Jun, 2024 21,164 2,158 2,876 4,106 92.9 10.2 Jul 30, 2024 J-GAAP
Jul - Sep, 2024 21,302 -377 -639 1,143 25.9 -1.8 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 23,203 2,457 3,061 3,591 81.8 10.6 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 22,661 1,535 1,676 3,121 71.6 6.8 May 7, 2025 J-GAAP
YoY +27.9% － +3,890.5% +10.6% +14.7%

Related Articles